$MASI (Masimo Corporation)

$MASI {{ '2016-03-02T13:19:44+0000' | timeago}} • Announcement

Monitoring technologies company $MASI said it will launch the SafetyNet Surveillance at the HIMSS 2016 Annual Conference and Exhibition in Las Vegas. SafetyNet Surveillance is a video surveillance system that provides real-time video images of a patient's room, including the patient with connected monitoring devices, to a central station.

$GILD {{ '2017-07-27T18:32:52+0000' | timeago}} • Announcement

$GILD declared a cash dividend of $0.52 per share of common stock for 3Q17, payable on September 28, 2017, to stockholders of record on September 15, 2017.

$CELG {{ '2017-07-27T14:01:16+0000' | timeago}} • Infographic

$CELG Celgene Earnings AlphaGraphic: Q2 2017 highlights

$VAR {{ '2017-07-27T13:52:33+0000' | timeago}} • Announcement

Medical devices company $VAR has entered into a strategic collaboration with PetCure Oncology for the treatment of pets suffering from cancer. Under the partnership, Varian's software suite will be deployed across PetCure's veterinary cancer care centers. PetCure will acquire six Varian Halcyon treatment systems for use in select sites in the US.

$CYH {{ '2017-07-27T12:33:35+0000' | timeago}} • Announcement

Hospital operator $CYH said it expects 2Q17 operating revenue to be about $4.1Bil, lower than $4.6Bil recorded last year. The company sees a net loss of $137MM or $1.22 per share for the quarter, compared to the $1.431Bil loss recorded in 2Q16. Adjusted EBITDA is estimated at $435MM, compared to $563MM a year earlier.

$GILD {{ '2017-07-26T21:10:46+0000' | timeago}} • Infographic

$GILD Gilead Sciences Earnings AlphaGraphic: Q2 2017 Highlights

$GILD {{ '2017-07-26T20:37:51+0000' | timeago}} • Announcement

$GILD revised its FY17 guidance. The company now expects net product sales to be $24-25.5Bil in FY17. Non-HCV product sales are expected to be $15.5-16Bil while HCV product sales are expected to be $8.5-9.5Bil. Adjusted product gross margin is expected to be 86-88% in FY17.

$GILD {{ '2017-07-26T20:33:53+0000' | timeago}} • Announcement

$GILD's total product sales for 2Q17 were $7Bil compared to $7.7Bil for 2Q16. Product sales were $5Bil in the US, $1.4Bil in Europe and $665MM in other locations during 2Q17. Antiviral product sales were $6.4Bil and Other product sales were $607MM for 2Q17.

$GILD {{ '2017-07-26T20:29:32+0000' | timeago}} • Announcement

$GILD posted a slight decrease in 2Q17 results. Net income was $3.1Bil or $2.33 per share compared to $3.5Bil or $2.58 per share in 2Q16. Adjusted net income was $3.4Bil or $2.56 per share in 2Q17. Total revenues were $7.1Bil compared to $7.8Bil in the prior-year period.

$CELG {{ '2017-07-25T20:43:29+0000' | timeago}} • Announcement

$CELG, which is set to release its earnings results on July 27, settles a lawsuit filed by Beverly Brown, a former saleswoman of the drugmaker, by paying a total of $280MM. The lawsuit claimed that Celgene used illegal marketing tactics to promote its cancer drugs Thalomid and Revlimid among doctors.

$GILD {{ '2017-07-24T13:41:56+0000' | timeago}} • Announcement

$GILD announced results from two Phase 3 studies evaluating the efficacy and safety of a fixed-dose combination of bictegravir (BIC) and emtricitabine/tenofovir alafenamide (FTC/TAF) for the treatment of HIV-1 infection in treatment-naïve adults. This regimen has been well tolerated with low rates of discontinuations due to adverse events.

$CYH {{ '2017-07-24T10:52:14+0000' | timeago}} • Announcement

$CYH's subsidiaries agreed to sell 126-bed Highlands Regional Medical Center in Sebring, Florida, and its associated assets to subsidiaries of $HCA. The transaction is expected to close in the fall of 2017.

$ISRG {{ '2017-07-21T12:26:16+0000' | timeago}} • Infographic

$ISRG Intuitive Surgical, Inc. Earnings AlphaGraphics: Q2 2017 highlights

$ISRG {{ '2017-07-20T20:21:13+0000' | timeago}} • Announcement

In 2Q17, $ISRG's service revenue rose 11% to $142MM while instrument and accessory revenue jumped 17% to $398MM. Intuitive Surgical ended the second quarter with $3.4Bil in cash, cash equivalents, and investments.

$ISRG {{ '2017-07-20T20:16:13+0000' | timeago}} • Announcement

In 2Q17, revenue for $ISRG jumped 13% to $756MM while net income soared 20% to $222MM or $5.77 per diluted share. Non-GAAP net income was $228MM or $5.95 per diluted share, with systems revenue increased by approximately 7% to $216MM.

$GILD {{ '2017-07-18T20:14:00+0000' | timeago}} • Announcement

$GILD said the US FDA has approved Vosevi tablets, a single-tablet regimen for the re-treatment of chronic hepatitis C virus (HCV) infection in adults previously treated with or without an NS5A inhibitor-containing regimen. The approval is based on data from the Phase 3 POLARIS-1 and POLARIS-4 studies.

$IDXX {{ '2017-07-18T10:56:31+0000' | timeago}} • Announcement

$IDXX unanimously elected Stuart Essig as a member of the company's BoD, effective July 12, 2017. In connection with Essig's election, the Board also increased its size from 8 to 9 members, effective July 12, 2017. Essig has been the Chairman of Integra LifeSciences Holdings Corp. since 2012.

$XRAY {{ '2017-07-14T15:40:42+0000' | timeago}} • Announcement

Dental solutions provider $XRAY declared a quarterly cash dividend of $0.0875 per common share. The corresponding annual rate has increased 12.9% to $0.35 per share from the prior annual rate of $0.31 per share. The dividend is payable on April 13, 2017 to shareholders of record on March 31, 2017.

$GILD {{ '2017-07-13T13:10:29+0000' | timeago}} • Announcement

$GILD said its Marketing Authorization Application for an investigational, once-daily single tablet regimen containing bictegravir and emtricitabine/tenofovir alafenamide, formulations for treatment of HIV-1 infection in adults, has been fully validated. Currently, they are under evaluation by the European Medicines Agency.

$LIVN {{ '2017-07-12T12:45:32+0000' | timeago}} • Announcement

$LIVN appointed Keyna Skeffington as SVP and General Counsel. Skeffington most recently served as Vice President of Legal – Corporate and Securities, Deputy General Counsel and Assistant Secretary at $MDT.

$CYH {{ '2017-07-12T11:46:04+0000' | timeago}} • Announcement

Hospital operator $CYH said its subsidiaries have signed a definitive agreement to sell Weatherford Regional Medical Center in Texas, and its associated assets, to the subsidiaries of $HCA. The transaction is expected to close later this year. The company is planning to divest a total of 30 hospitals.

Recent Transcripts

VAR (Varian Medical Systems, Inc.)
Wednesday, July 26 2017 - 9:00pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
BABY (Natus Medical Inc.)
Wednesday, July 26 2017 - 3:00pm
IART (Integra LifeSciences Holdings Corporation)
Wednesday, July 26 2017 - 12:30pm
ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
MDT (Medtronic plc)
Thursday, May 25 2017 - 12:00pm
ELMD (Electromed, Inc.)
Tuesday, May 16 2017 - 1:00pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
RMTI (Rockwell Medical, Inc.)
Tuesday, May 9 2017 - 8:30pm
STE (Steris Plc)
Tuesday, May 9 2017 - 2:00pm
NXTM (Nxstage Medical, Inc.)
Tuesday, May 9 2017 - 1:00pm
XRAY (DENTSPLY International Inc.)
Tuesday, May 9 2017 - 12:30pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
OFIX (Orthofix International N.V.)
Thursday, May 4 2017 - 8:30pm
IRIX (IRIDEX Corporation)
Wednesday, May 3 2017 - 9:30pm
MASI (Masimo Corporation)
Wednesday, May 3 2017 - 8:30pm
NVDQ (Novadaq Technologies Inc.)
Wednesday, May 3 2017 - 8:30pm
LIVN (LivaNova PLC)
Wednesday, May 3 2017 - 1:00pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm

AlphaGraphics you may like